“…The potential identification of a high-risk group of patients could allow the performance of more frequent controls in order to earlier diagnose cases with liver metastases that could be safely surgically excised [30]. Accordingly, in the last decade our research group reported some novel potential immunohistochemical factors with prognostic impact [5,[31][32][33][34][35], which may be included into the list of the classically reported markers of UM, such as tumor location, tumor size, extraocular invasion, cell type, pathological T stage and immunohistochemical staining with BAP1 [14]. Recently, Luo et al identified a ten-gene signature (SIRT3, HMCES, SLC44A3, TCTN1, STPG1, POMGNT2, RNF208, ANXA2P2, ULBP1 and CA12), able to better stratify the outcome of UM patients [36]; in detail, ANXA2P2, ULBP1, CA12 had a poor prognostic role, while the other genes a positive one.…”